Cell Source, Inc. (OTCPK: CLCS)
Health Care · Biotechnology · US
$0.49
-10.45% today · +25.2% 1Y
Cell Source, Inc. (OTCPK: CLCS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.63M and employs 1 people.
Over the last twelve months the share price has gained 25.2%, trading between 0.25 and 2.25.
Tweenvest scores Cell Source, Inc. across four factors: quality 19/100, value 61/100. Its strongest factor is value.
CLCS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.63M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.14
- Dividend yield
- —
- Beta (5Y)
- -201.61
- 52-week high
- $2.25
- 52-week low
- $0.25
- Avg volume (3M)
- —
- Shares outstanding
- 68.86M
- Employees
- 1
- Next earnings
- —
About Cell Source, Inc.
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
- ISIN
- US15114L1044
- Founded
- 2012
- Listed since
- May 1, 2014
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Holy Stone Healthcare Co., Ltd.TPEX: 4194 | $34.87M | NT$7.75 | -4.32% |
| Edesa Biotech, Inc.NasdaqCM: EDSA | $34.72M | $2.57 | -26.78% |
| Biomark Diagnostics Inc.DB: 20B | $34.02M | €0.28 | -4.70% |
| CervoMed Inc.NasdaqCM: CRVO | $33.87M | $2.24 | -30.43% |
| Mabion S.A.WSE: MAB | $33.59M | zł8.07 | +0.88% |
| Genetics Generation Advancement Corp.TPEX: 4160 | $33.50M | NT$38.80 | -0.26% |
| Vivoryon Therapeutics N.V.ENXTAM: VVY | $32.98M | €0.99 | -5.71% |
| QuantaMatrix Inc.KOSDAQ: A317690 | $32.77M | ₩2,170.00 | -6.26% |
Figures last refreshed Oct 18, 2026.